Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 996 participants.

Also called NCT02594501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 996 participants (enrolled count) (from the registry)
Sponsor
CeloNova BioSciences, Inc. (from the registry)
Registry
  • NCT NCT02594501
Other papers using this trial's data
  • Long term follow up of patients treated with a polymer coated non drug-eluting stent in the COBRA-REDUCE trial Cardiovascular revascularization medicine : including molecular interventions, 2025-06 DOI, PubMed 40050141
  • Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial Circulation. Cardiovascular interventions, 2024-10 DOI, PubMed 39405373

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Denmark, France, Germany, Italy, Latvia, Switzerland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02594501. Randomized; no masking; primary purpose treatment. Start 2016-02-05 (registry gives no type); primary completion 2021-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
Acronym
COBRA-REDUCE
Condition
Angina, Stable
Condition
Angina, Unstable
Condition
Anticoagulants
Intervention (Device)
COBRA PzF
Intervention (Device)
Drug Eluting Stent
Lead sponsor
CeloNova BioSciences, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02594501
Content hash
6796e3a73f65ebd89ceb9934807fdeee86213ebbb1f8a6949a3ebcb4f44ef277